Loading..
  • SynAct Pharma logoSVE
  • SynAct Pharma logoENG
  • About us
    • The Company in Brief
    • Vision
    • Mission
    • History
    • Organisation
    • Collaborations and Partnerships
  • Our Science
    • Resolving Inflammation
    • The Melanocortin System and Inflammation
    • SynAct’s Technology – Selective Melanocortin Stimulation
    • Scientific Advisory Board
  • Pipeline
    • Pipeline Overview
    • The resomelagon (AP1189) Development Program
      • Rheumatoid Arthritis
      • Membranous Nephropathy
      • Virus Induced Respiratory Insufficiency
    • Peptide Agonists
      • TXP-11
  • Investors
    • Capital Markets Day 2024
    • Investment highlights
    • Word from the CEO
    • Financial Reports
    • Presentations
    • The Share
      • Share price development
      • Ownership Structure
      • Insiders
      • Share Capital Development
    • Analyst Coverage
    • Calendar
    • Press Releases
    • Prospectus and rights issues
      • 2025
      • 2024
      • 2023
      • 2022
      • Older
  • Governance
    • General Meetings
    • Corporate Governance Report
    • Nomination Committee
    • Board of Directors
      • Remuneration Committee
      • Audit Committee
    • Management
    • Auditor
    • Articles of Association
    • Code of Conduct
  • Media
    • Press Releases
    • Synact in Media
    • Image Bank
    • Subscribe
  • Contact
March 20, 2024

Extraordinary General Meeting March 2024

On March 20, 2024, an extraordinary general meeting was held in SynAct Pharma AB (publ). 

Documents

  • Minutes from the extraordinary general meeting 2024
    March 20, 2024 English
    pdf
  • Press release – Bulletin from the extraordinary general meeting of SynAct Pharma AB
    March 20, 2024 English
    pdf
  • Power of Attorney
    pdf
  • Press release – Notice of extraordinary general meeting in SynAct Pharma AB
    February 7, 2024 English
    pdf
  • Governance
    • General Meetings
    • Corporate Governance Report
    • Nomination Committee
    • Board of Directors
      • Remuneration Committee
      • Audit Committee
    • Management
    • Auditor
    • Articles of Association
    • Code of Conduct

About Synact Pharma

SynAct Pharma is a clinical stage biotechnology company focused on resolving inflammation with melanocortin biology. Selective activation of the melanocortin system can help the immune system resolve excessive or chronic inflammation.

  • Privacy Policy
  • Cookies

Explore our Website

  • About us
  • Our Science
  • Pipeline
  • Investors
  • Governance
  • Media
  • Contact
  • LinkedIn

Subscribe